Valmark Advisers’s Tarsus Pharmaceuticals TARS Stock Holding History

Valmark Advisers’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$346K	Hold	5,500	–	–	﹤0.01%	581
2026 Q1	$386K	Hold	5,500	–	–	﹤0.01%	532
2025 Q4	$450K	Hold	5,500	–	–	0.01%	465
2025 Q3	$327K	Hold	5,500	–	–	﹤0.01%	525
2025 Q2	$223K	Hold	5,500	–	–	﹤0.01%	611
2025 Q1	$283K	Buy	+5,500	New	+$272K	﹤0.01%	529

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Valmark Advisers's TARS Position: Q2 2026 in Review

Valmark Advisers held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 5,500 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #581.

Valmark Advisers first reported a position in TARS in Q1 2025 and has held it in 6 quarters since. The position peaked at $450K in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Valmark Advisers held 5,500 shares of Tarsus Pharmaceuticals worth $346K as of Q2 2026.
Valmark Advisers left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
Tarsus Pharmaceuticals made up ﹤0.01% of Valmark Advisers's portfolio in Q2 2026, its #581 holding.
Valmark Advisers first reported a position in Tarsus Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Valmark Advisers's Tarsus Pharmaceuticals position peaked at $450K in Q4 2025.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Valmark Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.